RO115113B1 - Compoziţie farmaceutică - Google Patents

Compoziţie farmaceutică

Info

Publication number
RO115113B1
RO115113B1 RO97-02248A RO9702248A RO115113B1 RO 115113 B1 RO115113 B1 RO 115113B1 RO 9702248 A RO9702248 A RO 9702248A RO 115113 B1 RO115113 B1 RO 115113B1
Authority
RO
Romania
Prior art keywords
pharmaceutical composition
pharmaceutically acceptable
proteinase inhibitor
tocopherol
polyvinylpyrrolidone
Prior art date
Application number
RO97-02248A
Other languages
English (en)
Inventor
Carole Anne Bailey
Josephine Christine Ferdinando
Navnit Shah
Original Assignee
F. Hoffmann-La Roche Ag.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F. Hoffmann-La Roche Ag. filed Critical F. Hoffmann-La Roche Ag.
Priority claimed from PCT/EP1996/002431 external-priority patent/WO1996039142A1/en
Publication of RO115113B1 publication Critical patent/RO115113B1/ro

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Invenţia se referă la o compoziţie farmaceutică constituită din 0,5...3000 mg inhibitor de proteinază, săruri sau esteri ai acestuia, acceptabili din punct de vedere farmaceutic, o monogliceridăa acizilor graşi cu lanţ mediu C- C, care se află în raport faţă de inhibitorul de proteinază de cel puţin 1,5 până la cel puţin 3, cu sau fără până la 30% polivinilpirolidonă, cu sau fără până la 0,5% dl - alfa - tocoferol, precum şi alţi excipienţi acceptabili farmaceutic, rapoartele fiind exprimate în greutate.
RO97-02248A 1995-06-06 1996-06-04 Compoziţie farmaceutică RO115113B1 (ro)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US46849395A 1995-06-06 1995-06-06
US08/616,233 US6008228A (en) 1995-06-06 1996-05-07 Pharmaceutical compositions containing proteinase inhibitors
PCT/EP1996/002431 WO1996039142A1 (en) 1995-06-06 1996-06-04 Pharmaceutical composition comprising a proteinase inhibitor and a monoglyceride

Publications (1)

Publication Number Publication Date
RO115113B1 true RO115113B1 (ro) 1999-11-30

Family

ID=23860032

Family Applications (1)

Application Number Title Priority Date Filing Date
RO97-02248A RO115113B1 (ro) 1995-06-06 1996-06-04 Compoziţie farmaceutică

Country Status (18)

Country Link
US (1) US6008228A (ro)
KR (1) KR100267437B1 (ro)
AR (1) AR002759A1 (ro)
CO (1) CO4700448A1 (ro)
EG (1) EG24294A (ro)
HR (1) HRP960271B1 (ro)
MA (1) MA23900A1 (ro)
MY (1) MY116525A (ro)
PE (1) PE4398A1 (ro)
RO (1) RO115113B1 (ro)
SA (1) SA96170162B1 (ro)
SI (1) SI0831826T1 (ro)
SV (1) SV1996000040A (ro)
TW (1) TW452492B (ro)
UA (1) UA44316C2 (ro)
UY (1) UY24248A1 (ro)
YU (1) YU49308B (ro)
ZA (1) ZA964448B (ro)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9325445D0 (en) 1993-12-13 1994-02-16 Cortecs Ltd Pharmaceutical formulations
US5858401A (en) * 1996-01-22 1999-01-12 Sidmak Laboratories, Inc. Pharmaceutical composition for cyclosporines
IS4518A (is) * 1997-07-09 1999-01-10 Lyfjathroun Hf, The Icelandic Bio Pharmaceutical Group Nýtt lyfjaform fyrir bóluefni
US6353538B1 (en) * 1999-05-13 2002-03-05 Intel Corporation Protective cover and packaging for multi-chip memory modules
US7527807B2 (en) 2000-06-21 2009-05-05 Cubist Pharmaceuticals, Inc. Compositions and methods for increasing the oral absorption of antimicrobials
US6248360B1 (en) 2000-06-21 2001-06-19 International Health Management Associates, Inc. Complexes to improve oral absorption of poorly absorbable antibiotics
AU2002230918B2 (en) * 2000-10-31 2006-12-14 Boehringer Ingelheim Pharmaceuticals, Inc. Oral self-emulsifying formulations of pyranone protease inhibitors
CA2477321A1 (en) * 2002-02-25 2003-08-28 Lyfjathroun Hf Absorption enhancing agent
US7157489B2 (en) * 2002-03-12 2007-01-02 The Board Of Trustees Of The University Of Illinois HIV protease inhibitors
BR0202252A (pt) * 2002-06-12 2004-06-29 Cristalia Prod Quimicos Farm Composição farmacêutica solúvel estável para administração de inibidores da hiv protease e processo de obtenção de composições farmacêuticas concentradas para a administração de inibidores da hiv protease
US6855332B2 (en) * 2002-07-03 2005-02-15 Lyfjathroun Hf. Absorption promoting agent
AU2004308712A1 (en) * 2003-12-23 2005-07-14 Tibotec Pharmaceuticals Ltd. Self-microemulsifying drug delivery systems of a HIV protease inhibitor
EP1877041A2 (en) * 2005-04-29 2008-01-16 Cubist Pharmaceuticals, Inc. Therapeutic compositions
US20100222311A1 (en) * 2007-10-19 2010-09-02 Purdue Research Foundation Solid formulations of crystalline compounds

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4997851A (en) * 1987-12-31 1991-03-05 Isaacs Charles E Antiviral and antibacterial activity of fatty acids and monoglycerides
CA1340588C (en) * 1988-06-13 1999-06-08 Balraj Krishan Handa Amino acid derivatives
US5354866A (en) * 1989-05-23 1994-10-11 Abbott Laboratories Retroviral protease inhibiting compounds
DE3919982A1 (de) * 1989-06-19 1990-12-20 Liedtke Pharmed Gmbh Orale lipidarzneiform
GB8927913D0 (en) * 1989-12-11 1990-02-14 Hoffmann La Roche Amino acid derivatives
EP0448091B1 (en) * 1990-03-23 1998-08-05 The Green Cross Corporation Pharmaceutical composition containing slightly water-soluble drug
US5114957A (en) * 1990-05-08 1992-05-19 Biodor U.S. Holding Tocopherol-based antiviral agents and method of using same
CA2056911C (en) * 1990-12-11 1998-09-22 Yuuichi Nagano Hiv protease inhibitors
ATE183099T1 (de) * 1991-04-19 1999-08-15 Lds Technologies Inc Konvertierbare mikroemulsionsverbindungen
GB9113872D0 (en) * 1991-06-27 1991-08-14 Sandoz Ag Improvements in or relating to organic compounds
CN1071930A (zh) * 1991-07-10 1993-05-12 伊莱利利公司 用作治疗艾滋病的人免疫缺陷病毒蛋白酶的抑制剂
US5554728A (en) * 1991-07-23 1996-09-10 Nexstar Pharmaceuticals, Inc. Lipid conjugates of therapeutic peptides and protease inhibitors
US5516784A (en) * 1991-08-13 1996-05-14 Schering Corporation Anti-HIV (AIDS) agents
AU662434B2 (en) * 1992-08-07 1995-08-31 Sankyo Company Limited Peptides capable of inhibiting the activity of HIV protease, their preparation and their use
JPH08502492A (ja) * 1992-10-16 1996-03-19 スミスクライン・ビーチャム・コーポレイション 治療用ミクロエマルジョン
JPH08502490A (ja) * 1992-10-16 1996-03-19 スミスクライン・ビーチャム・コーポレイション 組成物
TW372972B (en) * 1992-10-23 1999-11-01 Novartis Ag Antiretroviral acyl compounds
US5538997A (en) * 1993-03-12 1996-07-23 Sandoz Ltd. 2,4-diamino-3-hydroxycarboxylic acid derivatives
US5318781A (en) * 1993-04-06 1994-06-07 Hoffmann-La Roche Inc. Absorption enhancement of antibiotics
SE9302135D0 (sv) * 1993-06-18 1993-06-18 Kabi Pharmacia Ab New pharmaceutical composition
IL110752A (en) * 1993-09-13 2000-07-26 Abbott Lab Liquid semi-solid or solid pharmaceutical composition for an HIV protease inhibitor

Also Published As

Publication number Publication date
UY24248A1 (es) 2000-12-29
HRP960271A2 (en) 1997-12-31
ZA964448B (en) 1996-12-06
TW452492B (en) 2001-09-01
AR002759A1 (es) 1998-04-29
KR100267437B1 (ko) 2000-12-01
HRP960271B1 (en) 2002-02-28
MA23900A1 (fr) 1996-12-31
PE4398A1 (es) 1998-02-28
EG24294A (en) 2009-01-08
SI0831826T1 (en) 2003-02-28
SV1996000040A (es) 1997-03-19
US6008228A (en) 1999-12-28
MY116525A (en) 2004-02-28
YU49308B (sh) 2005-06-10
CO4700448A1 (es) 1998-12-29
SA96170162B1 (ar) 2006-03-15
KR19990022425A (ko) 1999-03-25
YU33796A (sh) 1998-07-10
UA44316C2 (uk) 2002-02-15

Similar Documents

Publication Publication Date Title
RO115113B1 (ro) Compoziţie farmaceutică
EE200200572A (et) Pertsükvinniin, selle valmistamismeetod, kandseene liik ja farmatseutiline kompositsioon
ES2094350T3 (es) Cromano y tiocromanos con sustituyentes de feniletinilo en la posicion 7 que tienen actividad biologica de tipo retinoide.
RO116342B1 (ro) Compoziţie farmaceutică lichidă, orală
HUP0301107A2 (hu) Zsírsavak gyógyhatású kombinációi és alkalmazásuk
DE69904302D1 (de) Farnesyltransferase-inhibitoren mit piperidinstruktur und verfahren zu ihrer herstellung
DE69637096D1 (de) Stabile n-propargyl-1-aminoindan enthaltende zusammensetzungen
CA2219742A1 (en) N-heteroaryl-pyridinesulfonamide derivatives and their use as endothelin antagonists
FI962487A0 (fi) Rapamysiinijohdannaisia
YU42503A (sh) Arilovani furan-1 tiofen-amidi-karbonske kiseline sa blokirajućim dejstvom kalijumovog kanala
HUP0400644A2 (hu) Aszpirint tartalmazó gyógyászati kézítmények
BE902721A (fr) Nouvelles compositions cosmetiques permettant de retarder l'apparition d'un aspect gras des cheveux, et utilisation.
DE60002126D1 (de) Substituierte dimere Carboxamid-Derivate, Verfahren zu ihrer Herstellung und sie enthaltende pharmazeutische Zubereitungen
ATE130315T1 (de) Hirudin-derivate mit verzögerter wirkung.
ATE216236T1 (de) Metronidazolpräparate mit modifizierter freisetzung und verfahren für ihre herstellung und verwendung
MX9806229A (es) Derivados de benzo(c)quinolicina, su preparacion y uso como inhibidores de la 5alfa-reductasas.
IL117816A0 (en) N-subsituted azaheterocyclic compounds their preparation and pharmaceutical compositions containing them
SE9301112D0 (sv) A new composition
EP1269991A3 (en) Composition for topical use based on the ethylic ester of linoleic acid and on the triethyl ester of citric acid associated with suitable synergists
ATE344026T1 (de) Pharmazeutische formulierung mit einem nichtpeptidischen renin-hemmer und surfactant
CO4910113A1 (es) Composiciones farmaceuticas estabilizadas, a base de quinu- pristina y de dalfopristina y su preparacion
ES2074946A1 (es) Nuevos compuestos derivados de la 1,2-etanodiamina-n,n,n',n'-tetrasustituida.
WO1998043649A3 (en) Age production inhibitory composition comprising a maillard reaction inhibitor and vitamin b¿6?
RO115414B1 (ro) Compoziţie farmaceutică, intranazală
UA37211C2 (uk) Похідні 1,4-дигідропіридину у формі рацемату або енантіомерів, 2-хлор-3-ціанобензальдегід як проміжний продукт для їх одержання та фармацевтична композиція, що має антагоністичну активність по відношенню до катіонів кальцію